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Abstract Venous thromboembolism (VTE), including
deep vein thrombosis and pulmonary embolism (PE), is a
major cause of morbidity and mortality. Parenteral anti-
coagulant treatment with full-dose unfractioned heparin,
low-molecular-weight-heparin, or fondaparinux, followed
by oral treatment with the vitamin K antagonists, is rec-
ommended for the majority of patients. However, in the
presence of contraindications to anticoagulant treatment,
bleeding complications during antithrombotic treatment, or
VTE recurrences despite optimal anticoagulation, inter-
ruption of the inferior vena cava with a filter is a potential
option aimed to prevent life-threatening PE. Currently, the
vast majority of filters implanted worldwide are of the
permanent type, but their use is associated with a number
of long term complications. Non-permanent filters repre-
sent an important alternative, and in particular retrievable
filters are an attractive option because they may be either
left in place permanently or safely retrieved after a quite
long period when they become unnecessary. In this review,
we summarize the currently available literature regarding
retrievable vena cava filters and we discuss current
evidences on their efficacy and safety. Moreover, the
appropriate indications for their use in daily clinical prac-
tice are reviewed.
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Introduction
Full dose anticoagulation is the standard therapy of venous
thromboembolism (VTE). In case of contraindications to
anticoagulant treatment, bleeding complications during
antithrombotic treatment, or VTE recurrences despite
optimal anticoagulation, interruption of the inferior vena
cava (IVC) with a filter can be performed to prevent life-
threatening pulmonary embolism (PE) [1–4]. Currently, the
vast majority of the filters worldwide implanted are of the
permanent type [5–8]; nevertheless, placement of such
filters presents a number of long term complications.
Decousus et al. [9] demonstrated that in high-risk patients
with proximal deep vein thrombosis (DVT), the initial
benefit of IVC filters for the prevention of PE was coun-
terbalanced by an excess rate of recurrent DVT after two
years of follow-up. Moreover, one of the most important
long-term complications of definitive filters is the throm-
botic occlusion of the IVC, which is reported in 6 to 30%
of cases [2]; other significant complications include vena
cava perforation, filter dislocation, migration and rupture
[4]. Thus, alternative strategies for IVC interruption are
required, especially in patients with a long life expectancy
and in whom the period of risk from anticoagulant therapy
is short. Non-permanent filters are classified as temporary
or retrievable devices [2]. Temporary filters remain
attached to a wire or catheter that exits the skin; they are
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often difficult to manage and present frequent complica-
tions such as thrombosis, infections or migrations. They
must be removed within few days of placement, that is
often not enough to solve the clinical problem that had led
to their placement. Retrievable filters are a new generation
of IVC filters and may represent a more attractive option
because they may be either left in place permanently or
safely retrieved after a quite long period when they become
unnecessary [10, 11].
The purpose of the present review is to summarize the
currently available literature regarding retrievable IVC
filters, discussing on their efficacy and safety and assessing
the appropriate indications for their use. The available
results of the most important studies on retrievable filters
are summarized in Table 1.
Gunther Tulip filter
The Gunther Tulip filter consists of four struts of stainless
wheels with hooks at the end acting as anchors. The filter
can be placed either from the femoral or the jugular access,
and retrieval is from the right jugular site [12]. In the
registry of the Canadian Interventional Radiology Associ-
ation [12] 91 filters were placed in 90 patients; the main
reason for implantation was contraindication to anticoag-
ulation. Retrieval was attempted in 53 patients and was
successful in 52 (98%); mean implantation time was 9 days
(range 2–25 days). In the remaining 39 patients retrieval
was not attempted because of ongoing contraindication to
anticoagulation (n = 17) and large trapped emboli within
the filter (n = 10). Two patients developed filter occlusion
and 8% of the patients did require insertion of a permanent
filter after the temporary filter had been removed. Other
reports have demonstrated the feasibility of retrieval of
Gunther Tulip IVC device, after a maximum implantation
time of 139 days (mean 14 days), with a low rate of
recurrent PE while the filter was in place (0–3.6%); IVC
thrombosis occurred in 0–9.6% [13–17].
ALN filter
The ALN filter is a hydrodynamic steel retrievable IVC
filter. It has six short legs that ensure its adherence to the
IVC walls, and three long legs that guarantee the correct
central positioning into the vena cava [18]. ALN filter can
be placed from the femoral, brachial or jugular vein
approach, and can be retrieved only from the jugular
approach.
Table 1 Main results of retrievable filters studies
Study Filter Number of filters
removed and placed
Mean duration between filter
placement and retrieval (days)
Retrieval technical
success (%)
Ponchon [13] Gunther Tulip 8 of 10 12; range 8–14 88
Millward et al. [12] Gunther Tulip 52 of 91 9; range2–25 98
Offner et al. [14] Gunther Tulip 37 of 44 14; range 3–30 97
Asch [26] Recovery 24 of 32 53; range 5–134 100
Pieri et al. [18] ALN 7 of 18 63; range 49–192 100
Barral et al. [19] ALN 13 of 54 22; range 11–90 100
Pancione and Mecozzi [20] ALN 28 of 96 72; range 30–120 100
Morris et al. [15] Various 14 of 130 19; range 11–41 93
Imberti et al. [21] ALN 14 of 30 123; range 30–345 78
Grande et al. [27] Recovery 14 of 107 150; range 0–419 93
Oliva et al. [30] OptEase 21 of 27 11; range 5–14 100
Rosenthal et al. [34] OptEase 40 of 40 16; range 3–48 100
Ray et al. [17] Various 80 of 197 19; range 1–139 85
Stefanidis et al. [28] Various 47 of 83 142; range 17–475 87
Mismetti et al. [22] ALN 56 of220 51; range 6–352 93
Karmy et al. [48] Various 90 of 446 28.2 ± 26.3 78
Pancione et al. [23] ALN 71of 276 74; range 30–130 93
Pellerin et al. [24] ALN 122 of 123 93; range 6–722 99
de Villiers et al. [29] Recovery 22 of 54 48; range 7–90 96
Oliva et al. [30] Recovery 51 of 120 53; range 7–242 100
Binkert et al. [32] Recovery 61of 100 140; range 5–300 95
Onat et al. [36] OptEase 124 of 228 11; range 4–23 91
Kalva et al. [37] OptEase 14 of 71 9; range 5–21 85
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A number of trials have investigated the efficacy and
safety of long-term retrieval of the ALN device [18–24].
Pieri et al. [18] evaluated this device in 18 patients with
pelvic trauma (n = 11), hip replacement (n = 3) or for
primary prophylaxis before surgery in patients with very
high thromboembolic risk (n = 4). Filter retrieval was
attempted in 7 patients, being successful in all of them;
ALN was removed after a mean permanence of 63 days
(range 49–192) with no cases of PE, filter thrombosis or
trapped emboli inside the filters.
A French trial included 54 patients [19] submitted to a
ALN insertion; after a median follow-up of 4.3 months,
one case of PE and two of thrombosis of the filter were
registered, while in 13 of 13 cases filter retrievals were
successful after a median implantation period of 22 days
(range 11–90 days).
Pancione and Mecozzi [20] safely and easily implanted
ALN filters in 96 patients; the filter was successfully
removed in all the 28 patients in whom the removal was
attempted after a mean implantation time of 72 days (range
30–120 days).
A prospective, multicenter, clinical trial enrolled 30
patients undergoing placement of ALN filters [21]. Indica-
tions for implantation were acute VTE with contraindication
to anticoagulation in 26 cases (86%), primary prophylaxis
after major trauma in 2 cases (7%) or before surgery in 2
patients with very high thromboembolic risk (7%). The filter
was successfully placed in all patients. After a median follow-
up of 18.2 months, there were three cases (10%) of trapped
emboli within the filter, one case (3%) of asymptomatic
migration of the filter towards the heart and two DVT
recurrences (7%). ALN retrieval was attempted through
transjugular approach in 18 patients (60%) and the manoeu-
vre was successful in 14 of them. Interestingly, when the
decision of removal was taken within 3 months after the
implantation, the retrieval was possible in 10 of 10 patients
(100%); otherwise, when the attempt of retrieval was per-
formed more than 3 months after the implantation, the
retrieval was possible only in four of the eight patients (50%).
220 consecutive patients scheduled for placement of a
ALN filter were included in a prospective cohort study with
a 18-month follow-up [22]. Main indications for IVC fil-
tration were recurrent VTE despite adequate anticoagulation
therapy (10.9%), transient bleeding event (21.8%), defini-
tive contraindication for anticoagulant therapy (26.8%) or
obligation to stop anticoagulant therapy due to major sur-
gery, major trauma, or invasive procedures (37.7%). The
median duration of filter implantation was very long
(166 days; first to third quartiles, 34 to 478 days). During
follow-up, 17% (37 of 217 patients) had at least one VTE
event. Filter retrieval was attempted in 25.3% of the patients
after a median of 51 days (range 6 to 352 days) and was
successful in 92.7 of them.
An Italian study reported the results of a multicentre
experience concerning ALN permanent/removable vena
cava filters in a total of 276 patients [23]. The filter was
removed in 43 patients after 3 months and in 28 patients
after 6 months. In one case, due to incomplete opening of
the filter, immediate percutaneous removal was performed
and another filter was positioned. In five cases it was not
possible to remove the filter, in one case due to inexperi-
ence and in the remaining cases due to adhesion of the head
or claws of the filter to the wall of the vein.
A multicenter study evaluated the feasibility and results
of percutaneous removal of the ALN removable filter in a
large patient cohort [24]. 123 consecutive patients were
referred for percutaneous extraction of the ALN filter at
three centers. Filter removal was attempted after an
implantation period of 93 ± 15 days (range 6–722 days);
successful extraction was achieved in all but one case. No
immediate IVC complications were observed according to
the postimplantation cavography.
Recovery filter
The Recovery Nitinol Filter (RNF) is composed of 12
nitinol wires that extend from a nitinol sleeve and has six
arms and six legs [25].
Efficacy and safety of the Recovery filter were evaluated
in a preliminary study of 32 patients [26]. RNF was suc-
cessfully placed in 32 patients with no complications related
to filter insertion. Trapped thrombi were seen within the
filter in seven cases. In all the patients RNF was success-
fully retrieved after a mean implantation period of 53 days
(range 5–134 days). In two patients the filter was kept in
place for more than 100 days; notwithstanding, the removal
after such a long period was easily feasible and safe. There
were no episodes of PE or insertion-site thrombosis.
In a recent retrospective clinical trial 107 RNFs were
implanted in 106 patients with indication for temporary IVC
filtration [27] such as acute VTE with contraindication to
anticoagulation (33 cases), complications of anticoagulation
(8 cases), poor cardiopulmonary reserve (6 cases), large
clot burden (3 cases), PE while receiving anticoagulation
(1 case). In the other 55 patients filter was inserted as primary
prophylaxis without proven VTE, with multiple indications
for placement. Three patients (2.8%) had symptomatic PE
during placement of the filter; neither caval thrombosis nor
symptomatic filter migration occurred. RNF removal was
attempted only in 15 of 106 patients (14%) at a mean of
150 days after placement (range 0–419 days); the manoeu-
vre was successful in 14 of 15 patients, while in one patient
removal was impossible at 210 days after placement.
Favourable results were also reported by Stefanidis et al. [28]
who implanted 58 RNF mostly for trauma. Successful
removal was 85% (29/34) after a mean of 200 days (17–466).
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In a recently published series, 54 Recovery filters were
placed in Australian centres [29]. The most common
indication for filter placement in this series was established
thromboembolic disease with a temporary contraindication
to anticoagulation. Twenty-two filters were successfully
retrieved without complication. In one case, it was not
possible to retrieve the filter because of extensive contained
thrombus. No complication was experienced at filter
placement or retrieval; however, a fatal complication
occurred as a result of filter migration. Mean time from
placement to retrieval was 48 days (range 7–90 days).
A Recovery G2 inferior vena cava (IVC) filter was
placed in 120 consecutive patients in a single center [30].
Patients had DVT (n = 63), PE and DVT (n = 55), and
high risk for PE without recent thromboembolic disease
(n = 2). Indications for filter placement included contra-
indication to anticoagulation (n = 106), failure of antico-
agulation (n = 11), and prophylaxis in addition to
anticoagulation (n = 3). In the 51 patients who met the
criteria for filter removal, filter tilting ([15 degrees) was
seen in six patients (12%), small thrombi were seen in
filters of 15 patients (29%), presumed caval penetration
was seen in nine patients (18%), and caudal filter migration
was seen in two patients (3.9%). There were no fractures or
cephalic migrations. Removal attempts were successful in
all 51 patients (100%). The mean implantation time was
53.4 days (range 7–242 days).
Recovery (n = 128) and G2 (n = 113) filters were placed
in the IVCs of 241 patients with the intent of retrieval [31].
Filter placement was technically successful in 95% of
Recovery filters (n = 122) and 100% of G2 filters
(n = 113). Recovery filter retrieval was attempted in 55% of
patients (n = 71) at a mean of 228 days (range 0–838 days)
after filter placement. G2 filter retrieval was attempted in
55% of patients (n = 62) at a mean of 230 days (range
7–617 days) after filter placement. Technical success rates
of filter retrieval were 94% (n = 67) and 97% (n = 60) in
the Recovery and G2 filter groups, respectively. The G2 filter
group had significantly fewer cases of (i) filter tilt at place-
ment, (ii) filter tilt at attempted retrieval, and (iii) filter
fracture than the Recovery filter group. In the G2 filter group,
there was a significantly higher technical success rate of
filter placement and there were more cases of caudal filter
migration than in the Recovery filter group.
In a prospective, multicenter study 100 patients with
temporary indication for caval interruption with Recovery
G2 filter were enrolled [32]. There were 67 men and 33
women with a mean age of 52.1 years (range 19–82 years).
Indications for filter placement were trauma (n = 56),
perioperative risk (n = 16), and medical indications
(n = 28). Forty-two patients had VTE at filter placement.
Fifty-eight filters were placed prophylactically. Retrieval
was attempted in 61 patients. Fifty-eight of the 61 filters
(95%) were successfully retrieved after a mean dwell time
of 140 days (range 5–300 days). In all failed retrievals,
the filter tip was against the caval wall. Although there
were no cases of cranial migration, caudal migrations were
observed in 12% of cases (10 of 85 patients with a com-
plete data set). Other device-related complications included
filter fracture (1/85, 1.2%), filter tilt of more than 15
degrees (15/85, 18%), and leg penetration (16/61, 26%).
The recurrent pulmonary embolism (PE) rate was 2%, with
no PE in the 30-day period after filter retrival.
OptEase filter
The OptEase filter is a nitinol-MRI compatible filter and it
is the only filter retrievable from a femoral vein approach;
the filter has a symmetrical double-basket design with six
straights struts connecting the proximal and distal baskets
[33].
Several trials have recently investigated the efficacy and
safety of retrieval of the OptEase device [33–37].
Oliva et al. [33] enrolled in a multicenter study 27
patients; inclusion criteria were acute VTE with a contra-
indication to anticoagulation (n = 23) and primary pro-
phylaxis in very high thromboembolic risk patients
(n = 4). Retrieval was planned in 21 patients and in all of
them it was uneventful; in the remaining 6 patients removal
was not attempted as a result of ongoing contraindication to
anticoagulation (n = 3), large trapped emboli within the
filter (n = 2) and poor patient prognosis (n = 1). No
adverse events were seen during a mean time of implan-
tation of 11.1 days (range 5 to 14). In a multicenter clinical
trial 40 patients with clinical indication for temporary IVC
filtration underwent insertion and retrieval of OptEase [34].
No symptomatic PE, caval thrombosis or filter migration
occurred. In all the patients OptEase filter was successfully
removed after a mean of 16.4 days from insertion (range 3
to 28 days).
A non-randomized, multicenter trial prospectively
evaluated all patients receiving an OptEase vena cava filter
for the prevention of PE [35]. A 1-month postimplantation
follow-up examination was performed to determine
potential filter migration and the presence of symptomatic
thrombosis of the inferior vena cava (IVC) or lower
extremities. At 6-month postimplantation follow-up,
patients were again assessed for the safety and stability of
the filter and any clinical evidence of symptomatic
thrombosis. One hundred fifty patients were enrolled in this
study. Fifty-five patients (36.6%) were unable to complete
all of the necessary follow-up at 6 months. At 1 month,
filter migration and filter-related symptomatic deep vein
thrombosis was observed in one patient each (0.9 and
0.8%, respectively). At 6 months, no new cases of filter
migration or filter-related symptomatic thrombosis were
D. Imberti et al.
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observed. Filter tilting (C15 degrees off the IVC axis) was
observed in one patient at baseline (0.7%), four patients at
1-month follow-up (3.6%), and three patients (11.4%) at
6-month follow-up. Incidental findings on follow-up
radiographs included filter fracture in two patients (1.8%)
at 1 month and in one additional patient (4.3%) at
6 months. There were no clinical sequelae associated with
the filter fracture.
In a single center study, OptEase (permanent/retriev-
able; n = 228) or TrapEase (permanent; n = 30) vena cava
filters were placed in 258 patients [160 female and 98 male;
mean age 62 years (range 22 to 97)] [36]. Indications were
as follows: prophylaxis for PE (n = 239), contraindication
for anticoagulation in the presence of PE or DVT (n = 10),
and development of PE or DVT despite anticoagulation
(n = 9). Clinical PE did not develop in any of the patients.
However, radiologic signs of segmental PE were seen in 6
of 66 patients with follow-up imaging data. Migration or
fracture of the filter or cava perforation was not seen in any
of the patients. Except for a single case of asymptomatic
total cava thrombosis, no thrombotic occlusion was
observed. One hundred forty-one patients were scheduled
to undergo filter removal; however, 17 of them were not
suitable for such based on venography evaluation. Removal
was attempted in 124 patients and was successful in 115 of
these (mean duration of retention 11 days [range 4 to 23]).
Nine filters could not be removed.
In a single centre retrospective study, data of 71 patients
who received an OptEase filter were reviewed [37]. Thirty-
nine (55%) patients had symptoms of VTE before filter
placement. The indications for filter included contraindi-
cation to anticoagulation in 31 (44%) patients, prophylaxis
against PE in 29 (41%) patients, and failure of anticoagu-
lation in 11 (15%) patients. Seventy (99%) filters were
placed successfully. Retrieval was attempted in 14 (20%)
patients, and 12 filters were successfully retrieved. Clinical
follow-up was available for 20 ± 21 months. Symptoms of
postfilter PE and DVT occurred in 15% (n = 11) and 10%
(n = 7) patients, respectively. None of these patients had
computed tomography (CT)-proven PE, and only one had
ultrasound-proven new DVT. One patient had symptomatic
IVC occlusion. Follow-up abdominal CT in 20 patients
showed thrombus in the filter in two of them. There were
no instances of filter migration, filter tilt, or caval wall
penetration.
Indications for filter implantation
Contraindications to anticoagulation
According to the 8th ACCP Evidence-Based Clinical
Practice Guidelines on Antithrombotic and Thrombolytic
Therapy [3, 38], IVC filter placement is recommended
when there is a contraindication or complication of anti-
coagulant therapy in a patient with proximal DVT or PE.
Frequently, the contraindication to anticoagulation is tem-
porary (i.e. haemorragic stroke, trauma) and antithrombotic
therapy can be started as soon as it is resolved; for this
reason, retrievable IVC filters may be the ideal ‘‘bridge’’ to
anticoagulation for these patients [39]. Main indications for
retrievable vena cava filtration are reported in Table 2.
Trauma
Thromboprophylaxis is an important issue in patients with
major trauma [40], and PE is the cause of death in 20% of
severely injured patients [41]. Management of thrombo-
prophylaxis may be problematic because of the limited
efficacy of standard prevention (low dose heparin, sequen-
tial compression devices) and concern about potential
bleeding complications associated with anticoagulant
treatment. For these reasons, in the last few years an
increasing interest in the use of IVC filter for PE prophy-
laxis in this clinical setting has been observed [38].
Unfortunately, there are no randomized trials demonstrating
a clear benefit of IVC insertion in trauma patients [40–48].
Three small studies have reported a low rate of PE in
patients with severe polytrauma who underwent prophy-
lactic IVC filter insertion [46–48]. In a large prospective
study 127 multitrauma patients underwent a prophylactic
placement of a retrievable IVC filters (Gunther Tulip
n = 49; Recovery n = 41; OpTease n = 37), without any
complication [45]. Sixty-six patients underwent uneventful
retrieval of IVC filters after 5–116 days from implantation
(mean 71 days), while in 45 retrieval was not attempted
(41 due to contraindication to anticoagulation and 4 because
of trapped emboli within the filter). Finally, a retrospective
review of 446 trauma patients receiving retrievable IVC
filters in 21 different participating centers was performed
(Gunther Tulip n = 152; Recovery n = 224; OpTease
n = 37) [48]. Of interest, only 22% of the implanted filters
were retrieved; the main reason for which IVC filters were
not removed was because of loss to follow-up (31%). Of
115 patients in whom retrieval was attempted, removal
Table 2 Indications for retrievable IVC filters implantation
Appropriate indication
Temporary contraindication to anticoagulation
Potential indications
Prophylaxis in high risk trauma patients
Thrombolysis of ilio-caval thrombus
Pregnancy
Prophylaxis in high risk major orthopedic surgery
Prophylaxis in bariatric surgery
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failed for technical reasons in 15 patients and because of
significant residual thrombus within the filter in 10 patients.
Thrombolytic therapy
Systemic thrombolysis of proximal DVT and IVC thrombi
has resulted in several cases of fatal and non fatal PE;
therefore, prophylactic placement of IVC filters has been
proposed as a strategy to prevent PE in patients undergoing
thrombolysis. A European multicenter registry of tempo-
rary IVC filters used during systemic thrombolysis showed
an incidence of fatal PE of 2.1% and of non fatal PE of
1.6% [49]. To our knowledge, no data have been published
regarding retrievable IVC filters during thrombolysis for
DVT; because of their ease of use and of their advantages,
these devices appear as potentially attractive alternatives to
temporary filters. On the other hand, thrombolysis is in
principle contraindicated as a first approach to DVT
treatment [3], thus the potential use of filters in this setting
would be extremely limited.
Pregnancy
The overall incidence of VTE complications during preg-
nancy ranges from 0.2 to 1.2%, and is even higher during
the puerperium [50]. Since pregnancy is typically a tem-
porary risk factor for VTE, the use of a non-permanent
filter is particularly appealing when anticoagulation is
contraindicated. In a multicenter study, about 3% of all
temporary filters inserted were placed in pregnant women
who were undergoing caesarean section and thrombectomy
[51]. Few case reports showed that retrievable IVC filters
offer a safe and effective prevention to PE during preg-
nancy and puerperium and can be removed without com-
plications [52, 53]. On the other hand, there are no strong
data supporting the routine use of IVC filters in patients
suffering from acute DVT during pregnancy and this
device should be reserved for selected and specific
situations.
Major surgery associated with a high risk of DVT
Patients undergoing major orthopaedic surgery such as hip
and knee replacement carry a very high risk of VTE
complications [38]. Several case series showed the efficacy
of IVC filters in the prevention of PE in orthopaedic
patients, but none of these studies included a control group
and follow-up was of limited intensity and duration [23].
Furthermore many recent advances in pharmacological
prophylaxis (low-molecular weight heparin, synthetic
factor Xa and thrombin inhibitors) have contributed to
significantly reduce the risk of VTE in this setting.
Retrievable filters remain a useful option for highly
selected cases, i.e. patients at very high thromboembolic
risk because of a previous, recent massive PE or recurrent
VTE episodes or patients with a major contraindication to
pharmacologic therapy [21].
PE is considered the leading cause of death after bari-
atric surgery and common pharmacologic prophylactic
strategies have not been adequately tested in morbidly
obese patients [42, 54]. Placement of IVC filters has
become a common prophylactic strategy among some
bariatric surgeons, even if no prospective randomized
clinical trials have compared IVC filters with alternative
methods. However, filter placement can be challenging in
these patients, especially in the super obese (BMI [ 60). In
conclusion, there are no data supporting the routine use of
retrievable IVC filters in bariatric patients, and this device
should be reserved for specific situations.
Filter complications
The most important filter complications are reported in
Table 3.
Filter occlusion and inferior vena cava thrombosis
Occlusion of the filter is the most frequent complication of
vena cava filters and its incidence varies from 6 to 30%
of cases [39]. The reasons for this complication include
thrombogenicity of the device, natural cephalic progression
of DVT from the lower limb and entrapment of emboli
within the filter. Thrombosis of the filter and vena cava
occlusion may be associated with important clinical side
effects, including decreased protection against PE, migra-
tion of the filter, post-thrombotic syndrome and chronic
venous stasis. New generation filters offer the advantage of
a lower thrombogenicity compared with older ones.
Lower extremity vein thrombosis and post-thrombotic
syndrome
Vena cava filters themselves have sometimes been observed
to obstruct blood flow and contribute to an increase of
Table 3 Main complications of inferior vena cava filters
Complication Rate (%)
Complications from insertion 4–11
Insertion site thrombosis 2–28
IVC thrombosis 6–30
Filter migration 3–69
IVC perforation 9–24
Post-thrombotic syndrome 5–70
D. Imberti et al.
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recurrence of DVT of the lower extremity [9, 55]. For these
reason, the ACCP guidelines recommend, if the filter is
positioned as an alternative to anticoagulation, beginning of
adequate anticoagulant therapy as soon as possible if the
risk of bleeding resolves [3]. Otherwise, the optimal dura-
tion of anticoagulation in patients with permanent or
optional filter that is left in situ is still uncertain. A recently
published cohort study followed patients who had VTE,
followed by treatment with permanent IVC filter placement
and were anticoagulated long-term as soon as safety
allowed [55]. Patients underwent annual physical examin-
ations and ultrasound surveillance of the lower extremity
deep veins and of the IVC filter site. Symptomatic DVT
occurred in 24 of 121 patients (20%; 95% CI, 14–28%);
symptomatic PE (one fatal) was diagnosed in six patients
(5%; 95% CI, 2–10%). There were 45 episodes of filter clot
in 36 patients (30%; 95% CI, 22–38%). The rate of major
bleeding (6.6%) was similar to that of a concurrent persis-
tently anticoagulated cohort without IVC filters (5.8%).
Thus, the authors suggest indefinite anticoagulation to IVC
filter recipients if contraindications to anticoagulation
remit. On the contrary, other data of the literature, although
limited, do not seem to show significant differences in the
risk of DVT recurrences after IVC filter placement with or
without anticoagulation [56]. To sum up, in absence of
strong evidence in the literature and waiting for the results
of well-designed clinical trials, patients with IVC filter
should receive anticoagulation therapy according to current
guidelines in any specific clinical situation; it is not sug-
gested to continue indefinite anticoagulation just because
the filter is still present. Finally, the association of vena cava
filters with an increase of post-thrombotic syndrome is still
matter of debate; the available data suggest the potential
risk of post-thrombotic syndrome during long-term follow-
up in patients with permanent IVC filters [9, 57].
Vena cava perforation
Vena cava perforation is a usually asymptomatic compli-
cation, and without substantial clinical importance. Fre-
quently, it is only a radiological finding which occurs when
filter components extend more than 3 mm outside of the
wall of the IVC [58]. More rarely, bleeding complications
are associated with vena cava perforation, usually when the
filter leg is withdrawn leaving an open hole; other severe
consequences have been rarely reported [59].
Filter migration
The migration of the filter towards the heart is a potentially
life-threatening complication of IVC filters, even if, in the
majority of cases, migration is minor and does not result in
any significant morbidity [21]. A multicenter registry found
that temporary IVC filters had a dislocation rate of 4.8%;
no death due to this complication was reported [49]. A
recently published paper reported a high rate of strut
fracture (16%) and fragments embolization (25%) of the
Bard retrievable IVC filter; of interest, three out of 28
patients experienced life-threatening cardiac complications
related to migration of fragments to the heart [60].
Conclusions
Concerns regarding the long term safety of permanent IVC
filters and the problematic management of temporary
devices have created significant clinical interest in using
retrievable IVC filters to provide temporary protection
against PE. The results of our review support the important
role of retrievable filters in the management of selected
patients with VTE. Retrievable filters are a very attractive
alternative to either permanent or temporary filters, due to
their easier management and the possibility to be left in
place for a long time and removed when they become
unnecessary. This optimism must be tempered by impor-
tant unresolved issues, including the appropriate maximum
implantation time, the possibility to safely and effica-
ciously remove the filters without being compromised by
entrapped clots, and the use of anticoagulation during the
implantation and periremoval periods [10, 11]. In addition,
so far the real benefit associated with the use of retrievable
filters relies only on limited observational data and up-to-
date rigorous clinical trials are lacking. Well conducted
large prospective cohort studies or randomized trials are
strongly warranted to definitely clarify the beneficial role
of these devices.
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